Literature DB >> 24252445

Response to: Practical methods for incorporating summary time-to-event data into meta-analysis.

Yu Wang, Tingting Zeng1.   

Abstract

A response to and comment on Practical methods for incorporating summary time-to-event data into meta-analysis, by Jayne F Tierney et al.

Entities:  

Year:  2013        PMID: 24252445      PMCID: PMC3842792          DOI: 10.1186/1745-6215-14-391

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


Findings

As stated in the present article [1] by Tierney and colleagues, time-to-event outcomes were most appropriately analyzed using hazard ratios in meta-analyses. It provided step-by-step guidance on how to calculate hazard ratios and the associated statistics for individual trials, according to the information presented in the trial report. Among the 11 methods stated in this article, one of them presented suggested that, if it was reported in terms of P-value and events in each arm (and the randomization ratio was 1:1), these data can be used to estimate the O-E using Tierney’s equation 14: In the example of the present article, the log-rank P-value of 0.075 gave a z-score of 1.78 according to the latter part of Tierney’s equation 14. Nevertheless, we found 2-sided P-value of 0.075 gave a z-score of 1.78 by using the net tools [2]. But the z-score for the 2-sided P-value should be divided by 2 as described by Tierney and colleagues. Thus we can speculate that the z-score for a P-value of 0.075 should be 0.89, which was produced from 1.78/2. We also advertently found that a right-tailed P-value of 0.0375 gave a z-score of 1.78 by using the previous mentioned net tools [2], and 0.0375 by chance equals 0.075/2. So we speculated that the latter part of equation 14 required a more accurate representation of z-score and P-value as: z-score for (P-value/2). Tierney and colleagues reported that if a 1-sided P-value was reported, it can be used directly to calculate the z-score without dividing by 2. According to Li [3], a 1-sided P-value was used in log-rank test or Cox regression, and the exact P-value was given in the table for Chi-square (right-tailed test). However, we verified that a right-tailed P-value 0.075 gave a z-score of 1.44 by using the previous mentioned net tools [2]. Therefore, we can conclude that a 2-sided P-value can be used to directly to obtain the z-score. The latter part of equation 14 need to be modified into: z-score for P-value. Otherwise, a 1-sided P-value divided by 2 is required to obtain the z-score and the latter part of equation 14 should be expressed more exactly as: z-score for (P-value/2).

Authors’ reply

Jayne F Tierney, Lesley A Stewart, Davina Ghersi, Sarah Burdett and Matthew R Sydes. We thank the correspondents for bringing to our attention the unfortunate ambiguity in our article [1]. It is correct that the P-value that should be divided by 2 in equation 14 and not the z-score. This was the intention, and is more explicit in the original equation [4], provided in the appendix of Tierney and colleagues [1]: As suggested by the correspondents, equation 14 could be more precisely stated as: and the related explanatory text altered accordingly: “As well as the events on each arm and overall, the z-score for half the two-sided P-value is required” However, we disagree with the other points raised. It is suggested that one-sided P-values are used in log-rank tests and Cox regression models [3], whereas we find that it is standard practice to present two-sided (or two-tailed) P-values. Also, to our knowledge, all major statistical packages output two-sided P-values by default. It is therefore reasonable to assume that a P-value quoted in a trial publication will be two-sided unless otherwise stated, and to use this in equation 14. However, as described in the text [1]: “If a one-sided P-value is reported it can be used directly to obtain the z-score.” This is justified by equation 14 being derived algebraically from the definition of the log-rank statistic as a normally-distributed random variable, and by the fact that a one-sided P-value (assuming the most extreme direction of effect) is half the magnitude of the corresponding two-sided P-value. The correspondents go on to suggest that either a two-sided P-value or a one-sided P-value divided by 2 can be used directly in equation 14. In fact, this would produce an incorrect z-score and hazard ratio. Using the example in Tierney and colleagues, the z-score for the reported P-value of 0.075/2 (= 0.0375) is 1.78, as the correspondents themselves found using internet tools. This produces an O-E of 19.57 and hazard ratio of 0.85; the latter being identical to that reported in the trial publication [5]. If, as the correspondents suggested, we had used the reported P-value directly in equation 14, we would have obtained a z-score of 1.44, O-E of 15.82 and an incorrect hazard ratio of 0.88. Finally, researchers wishing to estimate hazard ratios from published time-to-event data need not rely on deriving them manually using the equations provided [1], but instead can use the Excel spreadsheet that accompanies the paper. Moreover, they can use this to cross-check hazard ratios derived from different methods of estimation.
  3 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Authors:  Gareth Griffiths; Reginald Hall; Richard Sylvester; Derek Raghavan; Mahesh K B Parmar
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

3.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

  3 in total
  16 in total

Review 1.  Scalpel versus electrosurgery for major abdominal incisions.

Authors:  Kittipat Charoenkwan; Zipporah Iheozor-Ejiofor; Kittipan Rerkasem; Elizabeth Matovinovic
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

Review 2.  Protease-modulating matrix treatments for healing venous leg ulcers.

Authors:  Maggie J Westby; Gill Norman; Jo C Dumville; Nikki Stubbs; Nicky Cullum
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

3.  Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jorge Henrique Bento de Sousa; Igor Lepski Calil; Francisco Tustumi; Douglas da Cunha Khalil; Guilherme Eduardo Gonçalves Felga; Rafael Antonio de Arruda Pecora; Marcio Dias de Almeida
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

Review 4.  Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack.

Authors:  Thomas P Zonneveld; Edo Richard; Mervyn DI Vergouwen; Paul J Nederkoorn; Rob de Haan; Yvo Bwem Roos; Nyika D Kruyt
Journal:  Cochrane Database Syst Rev       Date:  2018-07-19

Review 5.  Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Qingbao Li; Fang Liu; Yuan Zhang; Lei Fu; Cong Wang; Xuan Chen; Shanghui Guan; Xiangjiao Meng
Journal:  Oncotarget       Date:  2016-06-07

6.  Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R.

Authors:  Wei Deng; Yuanyuan Lei; Siyang Liu; Jinji Yang; Haiyan Tu; Honghong Yan; Yilong Wu
Journal:  Chin J Cancer Res       Date:  2016-06       Impact factor: 5.087

Review 7.  Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis.

Authors:  Manka Zhang; Huimin Ma; Jian Zhang; Lingling He; Xiaohui Ye; Xin Li
Journal:  Onco Targets Ther       Date:  2017-10-03       Impact factor: 4.147

Review 8.  Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.

Authors:  Jue Wang; Jun Yin; Qing Yang; Feng Ding; Xiao Chen; Bingjie Li; Xingsong Tian
Journal:  Oncotarget       Date:  2016-11-22

9.  Comprehensive evaluation of microRNA-10b in digestive system cancers reveals prognostic implication and signaling pathways associated with tumor progression.

Authors:  Yi Shen; Xiaolei Dai; Haibo Chen; Shuwei Zhai; Qiliang Peng; Shang Cai; Yaqun Zhu; Jian Huan; Yuntian Shen
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 10.  Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis.

Authors:  Qian Xia; Jianjun Liu; Cheng Wu; Shaoli Song; Linjun Tong; Gang Huang; Yuanbo Feng; Yansheng Jiang; Yewei Liu; Ting Yin; Yicheng Ni
Journal:  Cancer Imaging       Date:  2015-11-20       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.